JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2007; 50:261-267, doi:10.1016/j.jacc.2007.05.010 (Published online 12 June 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vermeersch, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Vermeersch, P.
Related Collections
Right arrowRelated Article

Increased Late Mortality After Sirolimus-Eluting Stents Versus Bare-Metal Stents in Diseased Saphenous Vein Grafts

Results From the Randomized DELAYED RRISC Trial

Paul Vermeersch, MD1, Pierfrancesco Agostoni, MD1,*, Stefan Verheye, MD, PhD, Paul Van den Heuvel, MD, Carl Convens, MD, Frank Van den Branden, MD, Glenn Van Langenhove, MD, PhD DELAYED RRISC (Death and Events at Long-term follow-up AnalYsis: Extended Duration of the Reduction of Restenosis In Saphenous vein grafts with Cypher stent) Investigators

Antwerp Cardiovascular Institute Middelheim, AZ Middelheim, Antwerp, Belgium.


Figure 1
View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1 Survival Curves

Kaplan-Meier estimates for survival by type of randomized stent (dotted blue line = bare-metal stent [BMS]; continuous red line = sirolimus-eluting stent [SES]).

 

Figure 2
View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2 TVR-Free Survival Curves

Kaplan-Meier estimates for target vessel revascularization (TVR)-free survival by type of randomized stent (dotted blue line = BMS; continuous red line = SES). Abbreviations as in Figure 1.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2007 by the American College of Cardiology Foundation.